Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):
Underlying Revenue declined -0.8% vs FY2018 Q1 pro-forma revenue[1]
· Takeda’s 14 global brands, with an aggregate revenue of 270.2 billion yen posted strong year-over-year growth of +22%. This growth mostly offset the negative impact from intensified competition, phasing, and generic erosion.
· Takeda’s 5 key business areas represent ~78% of revenues.
GI grew +8% spearheaded by ENTYVIO continuing to gain market share.
...
